Real-World Prevalence of PD-L1 Expression in Chinese Patients with Advanced or Metastatic NSCLC: Express II Study

被引：0
|
作者：
Lin, D. [1 ]
Yang, X. [1 ]
Jiang, L. [2 ]
Wang, W. [2 ]
Hou, Y. [3 ]
Li, Y. [4 ]
Jin, Y. [4 ]
Fan, X. [5 ]
Sun, W. [6 ]
Yun, J. [7 ]
Li, P. [7 ]
Kuang, D. [8 ]
Zhang, L. [9 ]
Ni, J. [10 ]
Mao, A. [11 ]
Tang, W. [11 ]
Liu, Z. [11 ]
Wang, J. [11 ]
Xiao, S. [11 ]
机构：
[1] Beijing Canc Hosp, Beijing, Peoples R China
[2] Sichuan Univ, West China Hosp, Chengdu, Peoples R China
[3] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China
[4] Fudan Univ, Shanghai Med Coll, Dept Pathol, Shanghai, Peoples R China
[5] Nanjing Drum Tower Hosp, Nanjing, Peoples R China
[6] Zhejiang Canc Hosp, Hangzhou, Zhejiang, Peoples R China
[7] Sun Yat Sen, Canc Hosp, Guangzhou, Peoples R China
[8] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Shanghai, Peoples R China
[9] Shanghai Pulm Hosp, Shanghai, Peoples R China
[10] First Hosp Jilin Univ, Eastern Div, Changchun, Peoples R China
[11] Bldg A,Headquarters Pk Phase 2,1582 Gumei Rd, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
Non-small cell lung cancer; programmed death-ligand 1; IHC;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P33.12
引用
收藏
页码：S410 / S410
页数：1
相关论文
共 50 条
  • [21] Real-World Survival Outcomes of Patients with High PD-L1 Advanced NSCLC Who Received Chemo-Immunotherapy vs Immunotherapy
    Cheng, J.
    Mckay, C.
    Bray, V. J.
    Yip, P. Y.
    Tognela, A.
    Kok, P. S.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S334 - S335
  • [22] PD-L1 expression in NSCLC
    Janzic, U.
    Kern, I.
    Janzic, A.
    Cavka, L.
    Cufer, T.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S58 - S59
  • [23] The prevalence of PD-L1 expression in patients with advanced oesophageal cancer: the EXCEED observational study
    Xue, Liyan
    Wang, Jiaqi
    Kuang, Dong
    Yun, Jingping
    Li, Yuan
    Jiang, Lili
    Wu, Daoyuan
    Duan, Pei
    Lu, Shixun
    Jin, Yan
    He, Du
    Qian, Jing
    Tang, Wenmin
    Wang, Yan
    Li, Jielin
    Ying, Jianming
    JOURNAL OF CLINICAL PATHOLOGY, 2025,
  • [24] Sugemalimab in locally advanced and advanced Chinese NSCLC: A real-world retrospective study
    Liu, Jiayu
    Wang, Yan
    Wang, Qi
    Yang, Ke
    Xie, Tongji
    Sun, Dantong
    Wu, Lige
    Li Junling
    Xing, Puyuan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [25] Comparison of Clinical Outcomes of Patients With Advanced NSCLC In Clinical Trials and in the Real World Received PD-1/PD-L1 Inhibitor
    Wang, H.
    Wei, C.
    Zhang, G. W.
    Zhang, M.
    Yan, X.
    Zhang, X.
    Niu, Y. Y.
    Yang, J.
    Ma, Z.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1017 - S1017
  • [26] Prevalence of PD-L1 Expression Rates in Different NSCLC Specimens
    Holmes, M.
    Mahar, A.
    Lum, T.
    Boyer, M.
    Kao, S.
    Cooper, W.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S506 - S506
  • [27] Comparative analysis of PD-L1 expression and molecular alterations in primary versus metastatic lung adenocarcinoma: a real-world study in China
    Chen, Gang
    Yu, Yang
    Qi, Youchao
    Li, Guangxu
    Li, Ning
    Meng, Fande
    Wang, Wujie
    Shen, Rong
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [28] Prevalence of PD-L1 Expression in Non-Small Cell Lung Cancer: a Real-World Australian Perspective
    Prabhakaran, S.
    Russell, P. A.
    Farrall, A. L.
    Asadi, K.
    Barrett, W.
    Cooper, C.
    Cooper, W.
    Duhig, E. E.
    Egan, M.
    Fox, S.
    Godbolt, D.
    Gupta, S.
    Cotton, S.
    Leslie, C.
    Leong, T.
    Moffat, D.
    Qiu, M.
    Sivasubramaniam, V.
    Snell, C.
    Skerman, J.
    Walsh, M.
    Whale, K.
    Klebe, S.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S479 - S479
  • [29] Digital pathology predicts PD-L1 expression in metastatic NSCLC patients treated with immunotherapy
    Prelaj, A.
    Sacco, M.
    Miskovic, V.
    Lorenzini, D.
    Trovo, F.
    Zec, A.
    Roisman, L. C.
    Provenzano, L.
    Proto, C.
    Spagnoletti, A.
    Silvestri, C.
    Meya, A.
    Pedrocchi, A.
    Sarris, E.
    Felip, E.
    Reck, M.
    De Braud, F. G. M.
    Lo Russo, G.
    Pearson, A. T.
    Garassino, M. C.
    ANNALS OF ONCOLOGY, 2024, 35 : S840 - S841
  • [30] Distribution of PD-L1 Tumor Expression by Assay Type in Patients with Metastatic NSCLC (MNSCLC)
    Velcheti, V.
    Cao, X.
    Liu, F.
    Patwardhan, P.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1779 - S1780
12345